anastassios g pittas, md ms associate professor of medicine

42
Vitamin D for Diabetes To D or not to D? “It isn’t so much the things we don’t know that get us in trouble. It’s the things we know that may not be so” Anastassios G Pittas, MD MS Associate Professor of Medicine Division of Endocrinology, Diabetes and Metabolism Tufts Medical Center [email protected] www.D2dstudy.org

Upload: moana

Post on 24-Feb-2016

35 views

Category:

Documents


0 download

DESCRIPTION

Vitamin D for Diabetes To D or not to D ? “It isn’t so much the things we don’t know that get us in trouble. It’s the things we know that may not be so”. Anastassios G Pittas, MD MS Associate Professor of Medicine Division of Endocrinology, Diabetes and Metabolism Tufts Medical Center - PowerPoint PPT Presentation

TRANSCRIPT

Page 1: Anastassios G Pittas, MD  MS Associate Professor of Medicine

Vitamin D for DiabetesTo D or not to D?

“It isn’t so much the things we don’t know that get us in trouble.

It’s the things we know that may not be so” Anastassios G Pittas, MD MSAssociate Professor of Medicine

Division of Endocrinology, Diabetes and MetabolismTufts Medical Center

[email protected]

Page 2: Anastassios G Pittas, MD  MS Associate Professor of Medicine

Please raise your hand if you take a specific vitamin D supplement (outside of a

multivitamin)

Page 3: Anastassios G Pittas, MD  MS Associate Professor of Medicine

Panacea (Greek goddess of healing)

Page 4: Anastassios G Pittas, MD  MS Associate Professor of Medicine

Vitamin D, the 21st century version of Panacea

Page 5: Anastassios G Pittas, MD  MS Associate Professor of Medicine

Vitamin D, the 21st century version of Panacea

Low vitamin D predicts fatal cancer, Pilz et al

Independent association of low vitamin D with all cause-and cardiovascular mortality, Dobnig et al

Low vitamin D predicts stroke, Pilz et al

Association of vitamin D deficiency with heart failure and sudden cardiac death, Pilz et al

Vitamin D supplementation might increase testosterone levels, Pilz et al

Vtamin D predicts breast cancer tumor size, Brouwers (abstract)

Page 6: Anastassios G Pittas, MD  MS Associate Professor of Medicine

Vitamin D is Big Business

Page 7: Anastassios G Pittas, MD  MS Associate Professor of Medicine

The Bipartisan Solution to U.S. Health Care Reform *

Grant et al 2009, Grant 2011

*Caveats (small print): analyses used “best-case scenario” data; method of economic burden calculations not provided

18%

82%

Due to low vitamin DOther

Total Health Care Expenditures saved, if all Europeans had 25(OH)D > 40 ng/ml

Page 8: Anastassios G Pittas, MD  MS Associate Professor of Medicine

Summary and Conclusions

• Population 25OHD is lower than it used to be… but, so what?

• Promising findings from observational research need confirmation in trials.

• Supplementation with vitamin D is unnatural and potentially dangerous.

Page 9: Anastassios G Pittas, MD  MS Associate Professor of Medicine

Vitamin D Dietary Sources are Limited

Holick NEJM

Page 10: Anastassios G Pittas, MD  MS Associate Professor of Medicine

Solar UVB Exposure in Decline

Page 11: Anastassios G Pittas, MD  MS Associate Professor of Medicine

Vitamin D Homeostasis

25OHD, a biomarker of vitamin D status

Rosen NEJM 2011

1988-1994 2001-2006 ~28 ~24

25OHD (ng/mL) trend over time

Looker et al AJCN 2008:88:1519 Looker et al NCHS Data Brief, No 59, March 2011

Page 12: Anastassios G Pittas, MD  MS Associate Professor of Medicine

Summary and Conclusions

• Population 25OHD is lower than it used to be… but, so what?

Page 13: Anastassios G Pittas, MD  MS Associate Professor of Medicine

Definition of Biomarker

• Biomarker of exposure– Validated measure to reflect intake or exposure– Example: 25-hydroxyvitamin D

Page 14: Anastassios G Pittas, MD  MS Associate Professor of Medicine

25OHD concentration (biomarker of exposure)after infrequent very high-dose vitamin D

supplementation

Sanders et al 2010 JAMA

500,000 IU of cholecalciferol (D3) yearly

Page 15: Anastassios G Pittas, MD  MS Associate Professor of Medicine

Definition of Biomarker

• Biomarker of exposure– Validated measure to reflect intake or exposure– Example: 25-hydroxyvitamin D

• Biomarker of effect (causal association)– Validated measure that is causally related to and

predictive of health outcome of interest– Example: LDL

Biomarker of Exposure ≠ Biomarker of Effect

Page 16: Anastassios G Pittas, MD  MS Associate Professor of Medicine

Prerequisites for Causal Association of Vitamin D with Disease

• Biological plausibility• Specificity [not required]• Temporal relationship: longitudinal studies• Strength of the association: high relative risk• Dose response (except in thresholds)• Experimental evidence

– Cessation/removal of exposure, intervention [RCT] • Consideration of alternative explanations• Coherence [consistency among studies]

Bradford Hill’s criteria

Page 17: Anastassios G Pittas, MD  MS Associate Professor of Medicine

VDRE

VDRRXR

1,25(OH)2D25(OH)D

1-hydroxylase

Ca2+

[Ca2+]i

Gene Expression

1,25(OH)2D25(OH)D

1-hydroxylase

gene

Vitamin D and Cellular Function Implications for Health beyond Bone

Pancreas (beta cell)Vasculature Immune cells SkinColonProstateBreastPlacentaBrain

1-hydroxylase expression

All cells

VDR expression

Page 18: Anastassios G Pittas, MD  MS Associate Professor of Medicine

Prerequisites for Causal Association of vitamin D with Diabetes

• Biological plausibility• Specificity [not required]• Temporal relationship: longitudinal studies• Strength of the association: high relative risk• Dose response (except in thresholds)• Experimental evidence

– Cessation/removal of exposure, intervention [RCT] • Consideration of alternative explanations• Coherence [consistency among studies]

X

Bradford Hill’s criteria

Page 19: Anastassios G Pittas, MD  MS Associate Professor of Medicine

Risk of Incident Type 2 Diabetes by Joint Categories of

Vitamin D and Calcium Intake

Pittas et al Diabetes Care 2006 29:3:650

Prospective Observational; Nurses Health Study cohort

Page 20: Anastassios G Pittas, MD  MS Associate Professor of Medicine

Risk of Incident Type 2 Diabetes by Joint Categories of

Vitamin D and Calcium Intake

Risk by 33%Risk by 33%

Pittas et al Diabetes Care 2006 29:3:650

Prospective Observational; Nurses Health Study cohort

Page 21: Anastassios G Pittas, MD  MS Associate Professor of Medicine

Association of 25OHD with Incident Type 2 Diabetes

5 10 15 20 25 30 35 40 45 500

0.2

0.4

0.6

0.8

1

1.2

1.4

1.6

1.8

Plasma 25(OH)D levels (ng/mL)

Odd

s ra

tio (9

5% C

I) of

type

2 d

iabe

tes

Pittas et al, Diabetes Care 2010

>33 ng/ml

Risk by 48%

Nested Case-Control; Nurses Health Study cohortSupported by NIDDK R21DK78867

p for trend 0.008

Page 22: Anastassios G Pittas, MD  MS Associate Professor of Medicine

Relative Risk.1 .25 .50 .75 1.0 2.0 5.0

Combined

Bolland_Women Anderson_Healthcare Population

Gagnon_AusDiab Grimnes_Smokers

Grimnes_Nonsmokers Robinson_WHI

Pittas_NHS_Women Knekt_MFH_Women

Knekt_MFH_Men Knekt_FMC_Women

Knekt_FMC_Men

0.65 (0.52-0.82)

0.90 (0.40-1.90) 0.53 (0.43-0.65)0.56 (0.36-0.86) 0.68 (0.29-1.61)0.73 (0.48-1.12)1.05 (0.62-1.76)0.52 (0.33-0.83)1.45 (0.58-3.62)0.17 (0.05-0.52)0.91 (0.37-2.23) 0.49 (0.15-1.64)

Relative Risk

Risk by 35% for 25OHD (ng/mL) >25-30 vs. <8-20

Association of 25OHD with Incident DiabetesMeta-analysis of Longitudinal Observational

Studies

Song et al (under review)

Page 23: Anastassios G Pittas, MD  MS Associate Professor of Medicine

Prerequisites for Causal Association of vitamin D with Diabetes

• Biological plausibility• Specificity [not required]• Temporal relationship: longitudinal studies• Strength of the association: high relative risk• Dose response (except in thresholds)• Experimental evidence

– Cessation/removal of exposure, intervention [RCT] • Consideration of alternative explanations• Coherence [consistency among studies]

X

Bradford Hill’s criteria

Page 24: Anastassios G Pittas, MD  MS Associate Professor of Medicine

Factors that Contribute to Vitamin D Deficiency/Insufficiency

Intake

Cutaneous synthesis

Season, Latitude > 43o, altitude; duration of sunlight; cloud cover; ozone cover; air pollution; time of day;Protective clothing; sunscreenPhysical inactivity; homebound

Diabetes

UVB Exposure

Skin Pigmentation

Vitamin D

25(OH)D

1,25(OH)2D 1,25(OH)2D

Bioavailability ( in obesity)Vit D

Milk

Dairy

“Medit diet”

Nutrient

Food

Food group

Dietary pattern

Aging, GeneticsBaseline 25OHD

>90%

Malabsorption Aging Lactose intolerance Gluten enteropathy Gastric surgery Biliary disease

Beta cell 1-a hydroxylase

Kidney 1-a hydroxylase

Page 25: Anastassios G Pittas, MD  MS Associate Professor of Medicine

Factors that Contribute to Vitamin D Deficiency/Insufficiency & Diabetes

Intake

Cutaneous synthesis

Season, Latitude > 43o, altitude; duration of sunlight; cloud cover; ozone cover; air pollution; time of day;Protective clothing; sunscreenPhysical inactivity; homebound

Diabetes

UVB Exposure

Skin Pigmentation

Vitamin D

25(OH)D

1,25(OH)2D 1,25(OH)2D

Malabsorption Aging Lactose intolerance Gluten enteropathy Gastric surgery Biliary disease

Bioavailability ( in obesity)Vit D

Milk

Dairy

“Medit diet”

Nutrient

Food

Food group

Dietary pattern

Aging, GeneticsBaseline 25OHD

>90%

Beta cell 1-a hydroxylase

Kidney 1-a hydroxylase

Page 26: Anastassios G Pittas, MD  MS Associate Professor of Medicine

ConfoundingIs vitamin D simply a marker of

increased risk for disease

Randomized Clinical Trials

Need

Association ≠ “supplementation would be beneficial”

Pitfalls of Observational Studies with Vitamin D and Disease

Page 27: Anastassios G Pittas, MD  MS Associate Professor of Medicine

Prerequisites for Causal Association of vitamin D with Diabetes

• Biological plausibility• Specificity [not required]• Temporal relationship: longitudinal studies• Strength of the association: high relative risk• Dose response (except in thresholds)• Experimental evidence

– Cessation/removal of exposure, intervention [RCT] • Consideration of alternative explanations• Coherence [consistency among studies]

X

Bradford Hill’s criteria

X

X

Page 28: Anastassios G Pittas, MD  MS Associate Professor of Medicine

Trials with vitamin D supplementation and type 2 Diabetes related outcomes

9 studies in participants without diabetes => no statistically significant effect on measures of glycemia

5 studies in patients with established type 2 Diabetes => 4 no statistically significant effect on measures of glycemia => 1 improvement on measures of glycemia

Nilas et al 1984; Pittas et al 2007; Do Boer et al 2008; Avenell et al 2009; Nagpal et al 2009; Zittermann et al 2009; Von Hurst et al, 2010; Jorde et al 2010; Grimnes et al 2011

Sugden et al 2008; Jorde and Figenschau 2009; Witham et al 2010; Nikooyeh et al 2012; Soric et al 2012

Page 29: Anastassios G Pittas, MD  MS Associate Professor of Medicine

Limitations of Published Trials on Vitamin D Supplementation and Type 2 Diabetes

• Small, underpowered studies• Inadequate duration• Large dropout rates [20-40%]• Post-hoc analyses• Choice of vitamin D regimen

– Large infrequent doses • Populations studied

– Normal glucose tolerance [unlikely to benefit] – Established type 2 diabetes [difficult to show]

Page 30: Anastassios G Pittas, MD  MS Associate Professor of Medicine

Effect of Vitamin D3 Supplementation (2,000 IU/day)

on Disposition Index (beta-cell function) and HbA1c

Mitri et al AJCN 2011

Supported by NIDDK/ODS R01DK76092

Participants at risk for diabetes (IFG, IGT)

p=0.08

Page 31: Anastassios G Pittas, MD  MS Associate Professor of Medicine

Summary and Conclusions

• Population 25OHD is lower than it used to be… but, so what?

• Promising findings from observational research need confirmation in trials.

• Supplementation with vitamin D is unnatural and potentially dangerous.

Page 32: Anastassios G Pittas, MD  MS Associate Professor of Medicine

Proposed solutions to decreased UVB exposure and altered lifestyle

* Disclaimer : There is no fruit in “Fruity” Pebbles

Take a large vitamin D pill daily (weekly, monthly or [why not] yearly

Alternatively, supplement all food with vitamin D

The sunshine pill

Page 33: Anastassios G Pittas, MD  MS Associate Professor of Medicine

25OHD concentration (biomarker of exposure)after infrequent very high-dose vitamin D

supplementation

Sanders et al 2010 JAMA

500,000 IU of cholecalciferol (D3) yearly

Page 34: Anastassios G Pittas, MD  MS Associate Professor of Medicine

Fractures (biomarker of effect?)after infrequent very high-dose vitamin D

supplementation

Sanders et al 2010 JAMA

500,000 IU of cholecalciferol (D3) yearly

High infrequent (non-daily) doses of vitamin D may be metabolized differently and have an unfavorable benefit/risk profile

Page 35: Anastassios G Pittas, MD  MS Associate Professor of Medicine

Summary and Conclusions

• Population 25OHD is lower than it used to be… but, so what?

• Promising findings from observational research need confirmation in trials.

• Supplementation with vitamin D is unnatural and potentially dangerous.

Page 36: Anastassios G Pittas, MD  MS Associate Professor of Medicine

Vitamin D Recommended IntakeInstitute of Medicine (U.S.) 2011 Report *

≤ 70 years 600 IU

RDA 1

800 IU> 70 years

UL 2

4,000 IU

4,000 IU

* RDA for skeletal outcomes (fractures and falls) ONLYUnder conditions of minimal sun exposure

Applicable to normal healthy population groups1Recommended Dietary Allowance, intake that meets needs of 97.5% of

healthy population2Tolerable Upper Intake Level, above which potential risk of adverse effects

may increase with chronic use. UL is not highest dose recommended

Page 37: Anastassios G Pittas, MD  MS Associate Professor of Medicine

Optimal 25OHD ConcentrationInstitute of Medicine (U.S.) 2011

Sufficiency

Deficiency

30 - 50

20 - 29

< 12

ng/mL

Rickets, Osteomalacia

Risk of Chronic Disease ????

12 - 19Inadequacy

Risk of Skeletal Outcomes ONLY

Page 38: Anastassios G Pittas, MD  MS Associate Professor of Medicine

Optimal 25OHD ConcentrationEndocrine Society, 2011

Inadequacy

Deficiency

30 - 50

20 - 29

< 12

ng/mL

Rickets, Osteomalacia

Risk of Skeletal Outcomes

12 - 19Inadequacy

Page 39: Anastassios G Pittas, MD  MS Associate Professor of Medicine

Which 25OHD threshold to follow, IOM or Endocrine Society?

IOM Endo Society0%

20%

40%

60%

80%

100% 25 77

Insuf -fi-ciencySufficiency

~100 million adultsAnn Intern Med. 2012;156(9):627-634

22 ng/mL 30 ng/mL

Page 40: Anastassios G Pittas, MD  MS Associate Professor of Medicine

All I needed to know I learned in kindergartenHard lessons learned along the alphabet

A, B, C, D, E,

Is Vitamin D the new vitamin A, the new vitamin B, the new vitamin C, the

new vitamin E ?

Page 41: Anastassios G Pittas, MD  MS Associate Professor of Medicine

Vitamin D is flying off shelves

Local Pharmacy October 2012

Page 42: Anastassios G Pittas, MD  MS Associate Professor of Medicine